Pfizer Abandons Twice-Daily Weight Loss Pill Following Dismal Study Findings
Pfizer said it would not move its twice-daily oral weight-loss drug danuglipron into late-stage research after patients experienced nausea and vomiting.
Stay updated with breaking news from Active Ingredient. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer said it would not move its twice-daily oral weight-loss drug danuglipron into late-stage research after patients experienced nausea and vomiting.
Boxwood is a broadleaf evergreen shrub that keeps its leaves all winter, and they are not needle-like as pine or spruce are. Even though boxwood leaves are tiny, they’re referred
Pfizer said it would not move its twice-daily oral weight-loss drug danuglipron into late-stage research after patients experienced nausea and vomiting.
It is five years this month since a ground-breaking change in UK healthcare history happened – with doctors being able to prescribe cannabis-based medicines for the first time.
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The